Effects of NMDA receptor antagonists on acute μ-opioid analgesia in the rat

Mixed research findings have led to a debate regarding the effect of N-metbyl-D-aspartate (NMDA) receptor antagonists on opiate analgesia. NMDA antagonists have been found in various studies to enhance, to inhibit, or to have no effect on opiate analgesia. The present research used a single protocol to explore the effects of six NMDA receptor antagonists on acute morphine (3.0 mg/kg sc) and fentanyl (0.05 mg/kg sc) analgesia in adult male Sprague-Dawley rats. NMDA receptor antagonists were selected based on their abilities to block various sites on the NMDA receptor complex, including the noncompetitive antagonists MK-801 (0.1 and 0.3 mg/kg ip), dextromethorphan (10.0 and 30.0 mg/kg ip), and memantine (3.0 and 10.0 mg/kg ip), a glycine site antagonist, (+)-HA-966 (10.0 and 30.0 mg/kg ip), a competitive antagonist, LY235959 (1.0 and 3.0 mg/kg ip), and a polyamine site antagonist, ifenprodil (1.0 and 3.0 mg/kg ip). Analgesia was assessed using the tail-flick test. A single dose of each opiate was used. The low doses of the antagonists, which are known to produce significant neural and behavioral actions at NMDA receptors, had no effect on morphine or fentanyl analgesia. At the higher doses, morphine analgesia was significantly enhanced by LY235959 (3.0 mg/kg), and fentanyl analgesia was significantly enhanced by LY235959 (3.0 mg/kg), dextromethorphan (30.0 mg/kg), and (+)-HA-966 (30.0 mg/kg). Enhancement of analgesia occurred without any apparent adverse side effects. None of the NMDA antagonists affected tail-flick responses on their own, except the higher dose of LY235959 (3.0 mg/kg), which produced a mild analgesic effect. Because no consistent effects were observed, the data suggest that NMDA receptors are not involved in acute p-opioid analgesia. The mechanisms underlying the enhancement of opiate analgesia by selected NMDA antagonists, such as LY235959, dextromethorphan, and (+)-HA-966, remain to be determined. (C) 2003 Elsevier Inc. All rights reserved.